Lineage Cell Therapeutics (LCTX) Stock Price, Quote, News & History | Benzinga

Lineage Cell Therapeutics Inc (LCTX) Stock Price, Quote, News & History

LCTXAMEX

Trade with Public

Trade with Public

$1.08

-0.02-1.82%

At close: Aug 20, 5:00 PM EST

$1.07

-0.0097-0.9%

After Hours: 4:07 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$1.09

Close

$1.08

Volume / Avg.

1.47M / 1.36M

Day Range

$1.04 - $1.10

52 Wk Range

1.00 - 2.09

Market Cap

$270.69M

P/E Ratio

-

Dividend Yield

-

Exchange

AMEX

RSI

43

Short Interest

19.39%

Days to Cover

26.2

Recent Lineage Cell Therapeutics Inc News

Service Properties Trust, ConocoPhillips And Other Big Stocks Moving Lower In Monday's Pre-Market Session

US stock futures up, Nasdaq 100 gains 100 pts. Service Properties Trust (SVC) drops 4% in pre-market trading. Other decliners: MGRT, UP, CDZI, LCTX, KEP, AUTL, EOG, ANGX, COP.

Avi Kapoor

Snowflake, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Avi Kapoor

Two Biotech Stocks Poised For Big Moves On Monday

David Pinsen

Lineage Cell Therapeutics, Longeveron And 2 Other Stocks Under $2 Insiders Are Buying

The Dow Jones index closed higher by around 25 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Avi Kapoor

EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics

Lineage Cell Therapeutics Inc (NYSE: LCTX) has initiated certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the company’s exclusive option and license agreement with Eterna Therapeutics Inc (NASDAQ:

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-23.82M

Investing Cash Flow (TTM)

-13.71M

Financing Cash Flow (TTM)

32.24M

Free Cash Flow (TTM)

-24.39M

Capital Expenditure (TTM)

-574.00K

Net Change in Cash (TTM)

-5.29M

Analyst Trends and Forecast

3

Mar

1

Apr

1

May

1

Jul

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$224.61M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

20.79

PB Ratio (TTM)

4.57

Earnings Yield % (TTM)

-17.27%

Earnings Yield % (FWD)

-7.27%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.24

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$54.00K

Total Cash

$37.35M

Debt to Equity

0.04

Issuance of Debt (TTM)

-$54.00K

Repayment of Debt (TTM)

-$54.00K

Key Statistics

Open

$1.09

Close

$1.08

Volume / Avg.

1.47M / 1.36M

Day Range

$1.04 - $1.10

52 Wk Range

1.00 - 2.09

Market Cap

$270.69M

P/E Ratio

-

Dividend Yield

-

Exchange

AMEX

RSI

43

Short Interest

19.39%

Days to Cover

26.2

About

Sector

Health Care

Industry

Biotechnology

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonanc...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Lineage Cell Therapeutics (LCTX) stock?

A

You can purchase shares of Lineage Cell Therapeutics (AMEX:LCTX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Lineage Cell Therapeutics (LCTX) competitors?

A

There are no as such competitors for Lineage Cell Therapeutics.

Q

What is the forecast, or price target, for Lineage Cell Therapeutics (LCTX) stock?

A

Lineage Cell Therapeutics has a consensus price target of $5.43.

Q

What is the current price for Lineage Cell Therapeutics (LCTX)?

A

The stock price for Lineage Cell Therapeutics (AMEX: LCTX) is $1.0703 last updated August 20, 2026 at 4:07 PM EDT.

Q

Does Lineage Cell Therapeutics (LCTX) pay a dividend?

A

There are no upcoming dividends for Lineage Cell Therapeutics.

Q

When is Lineage Cell Therapeutics (AMEX:LCTX) reporting earnings?

A

Lineage Cell Therapeutics does not have any upcoming earnings scheduled.

Q

Is Lineage Cell Therapeutics (LCTX) going to split?

A

There is no upcoming split for Lineage Cell Therapeutics.

Q

What sector and industry does Lineage Cell Therapeutics (LCTX) operate in?

A

Lineage Cell Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the AMEX.